Laura Wingate on the Unique Situation of 7 Adalimumab Biosimilars Coming to Market at Once

Despite having 8 adalimumab biosimilars on the market now, patients may only see 1 or 2 available through their insurance, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.

Related Keywords

United States , Laura Wingate , Crohn Colitis Foundation , Biosimilars , Payers , Adalimumab , Humira , Remicade , Infliximab ,